{"pmid":32310242,"pmcid":"PMC7162640","title":"The Known into the Unknown: Brugada syndrome and COVID-19.","text":["The Known into the Unknown: Brugada syndrome and COVID-19.","JACC Case Rep","Sorgente, Antonio","Capulzini, Lucio","Brugada, Pedro","32310242"],"journal":"JACC Case Rep","authors":["Sorgente, Antonio","Capulzini, Lucio","Brugada, Pedro"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32310242","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jaccas.2020.04.006","keywords":["brugada syndrome","covid-19","sudden cardiac death"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Brugada"],"_version_":1664632501411250177,"score":8.518259,"similar":[{"pmid":32292696,"pmcid":"PMC7138191","title":"COVID-19 Infection Unmasking Brugada Syndrome.","text":["COVID-19 Infection Unmasking Brugada Syndrome.","HeartRhythm Case Rep","Chang, David","Saleh, Moussa","Garcia-Bengo, Youssef","Choi, Evan","Epstein, Laurence","Willner, Jonathan","32292696"],"journal":"HeartRhythm Case Rep","authors":["Chang, David","Saleh, Moussa","Garcia-Bengo, Youssef","Choi, Evan","Epstein, Laurence","Willner, Jonathan"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292696","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.hrcr.2020.03.012","keywords":["brugada syndrome","covid-19","coronavirus","electrocardiogram","syncope"],"source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664636192709148672,"score":143.67102},{"pmid":32188753,"pmcid":"PMC7082143","title":"COVID-19: Knowns, Unknowns, and Questions.","text":["COVID-19: Knowns, Unknowns, and Questions.","The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from the Hubei province in China in late 2019 demonstrates the epidemic potential of coronaviruses. The rapid spread of this virus across the world in only 2 months highlights the transmissibility of this family of viruses and the significant morbidity and mortality that they can cause. We highlight the current state of knowledge of coronavirus biology while answering questions concerning the current outbreak of SARS-CoV-2.","mSphere","Weston, Stuart","Frieman, Matthew B","32188753"],"abstract":["The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from the Hubei province in China in late 2019 demonstrates the epidemic potential of coronaviruses. The rapid spread of this virus across the world in only 2 months highlights the transmissibility of this family of viruses and the significant morbidity and mortality that they can cause. We highlight the current state of knowledge of coronavirus biology while answering questions concerning the current outbreak of SARS-CoV-2."],"journal":"mSphere","authors":["Weston, Stuart","Frieman, Matthew B"],"date":"2020-03-20T11:00:00Z","year":2020,"_id":"32188753","week":"202012|Mar 16 - Mar 22","doi":"10.1128/mSphere.00203-20","keywords":["covid-19","sars","sars-cov-2","coronavirus"],"source":"PubMed","topics":["Mechanism","Treatment","Transmission"],"weight":1,"locations":["Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640874529685504,"score":112.729836},{"pmid":32244059,"pmcid":"PMC7156157","title":"SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes.","text":["SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes.","Ever since the first case was reported at the end of 2019, the SARS-COV-2 virus and associated lung disease COVID-19 has spread throughout the world and has become a pandemic. In particular, the high transmission rate of the virus has made it a threat to public health globally. Currently, there is no proven effective therapy against the virus, and the impact on other diseases is also uncertain, especially inherited arrhythmia syndrome. Arrhythmogenic effect of COVID-19 can be expected, potentially contributing to disease outcome. This may be of importance for patients with an increased risk for cardiac arrhythmias, either secondary to acquired conditions or co-morbidities or consequent to inherited syndromes. Management of patients with inherited arrhythmia syndromes such as Long QT syndrome, Brugada syndrome, Short QT syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia in the setting of the COVID-19 pandemic may prove particularly challenging. Depending on the inherited defect involved, these patients may be susceptible to pro-arrhythmic effects of COVID-19-related issues such as fever, stress, electrolyte disturbances and use of antiviral drugs. We here describe the potential COVID-19 associated risks and therapeutic considerations for patients with distinct inherited arrhythmia syndromes and provide recommendations, pending local possibilities, for their monitoring and management during this pandemic.","Heart Rhythm","Wu, Cheng-I","Postema, Pieter G","Arbelo, Elena","Behr, Elijah R","Bezzina, Connie R","Napolitano, Carlo","Robyns, Tomas","Probst, Vincent","Schulze-Bahr, Eric","Remme, Carol Ann","Wilde, Arthur A M","32244059"],"abstract":["Ever since the first case was reported at the end of 2019, the SARS-COV-2 virus and associated lung disease COVID-19 has spread throughout the world and has become a pandemic. In particular, the high transmission rate of the virus has made it a threat to public health globally. Currently, there is no proven effective therapy against the virus, and the impact on other diseases is also uncertain, especially inherited arrhythmia syndrome. Arrhythmogenic effect of COVID-19 can be expected, potentially contributing to disease outcome. This may be of importance for patients with an increased risk for cardiac arrhythmias, either secondary to acquired conditions or co-morbidities or consequent to inherited syndromes. Management of patients with inherited arrhythmia syndromes such as Long QT syndrome, Brugada syndrome, Short QT syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia in the setting of the COVID-19 pandemic may prove particularly challenging. Depending on the inherited defect involved, these patients may be susceptible to pro-arrhythmic effects of COVID-19-related issues such as fever, stress, electrolyte disturbances and use of antiviral drugs. We here describe the potential COVID-19 associated risks and therapeutic considerations for patients with distinct inherited arrhythmia syndromes and provide recommendations, pending local possibilities, for their monitoring and management during this pandemic."],"journal":"Heart Rhythm","authors":["Wu, Cheng-I","Postema, Pieter G","Arbelo, Elena","Behr, Elijah R","Bezzina, Connie R","Napolitano, Carlo","Robyns, Tomas","Probst, Vincent","Schulze-Bahr, Eric","Remme, Carol Ann","Wilde, Arthur A M"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32244059","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.hrthm.2020.03.024","keywords":["brugada syndrome","covid-19","catecholaminergic polymorphic ventricular tachycardia","long qt syndrome","sars-cov-2","short qt syndrome"],"source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"locations":["Brugada"],"_version_":1664638249360949248,"score":94.35828},{"pmid":32259155,"pmcid":"PMC7117791","title":"Covid 19 pandemic and gynaecological laparoscopic surgery: knowns and unknowns.","text":["Covid 19 pandemic and gynaecological laparoscopic surgery: knowns and unknowns.","The worldwide impact of COVID 19 continues to be felt as hospitals in all countries reduce elective and non-urgent cases to allow staffing and resources to be deployed elsewhere. Urgent gynaecological and cancer procedures are continuing, and it is imperative all theatre staff are protected and risks of SARS-CoV-2 viral transmission reduced when operating on asymptomatic, suspected or confirmed COVID 19 patients. In particular, there are concerns relating to the transmission of COVID 19 during gynaecological laparoscopic surgery, arising from the potential generation of SARS-CoV-2 contaminated aerosols from CO2 leakage and the creation of smoke from the use of energy devices. The aim of this paper is to review all the up to date evidence, including experiences from China and Italy, to guide the safe management of such patients when undergoing gynaecological procedures.","Facts Views Vis Obgyn","Mallick, R","Odejinmi, F","Clark, T J","32259155"],"abstract":["The worldwide impact of COVID 19 continues to be felt as hospitals in all countries reduce elective and non-urgent cases to allow staffing and resources to be deployed elsewhere. Urgent gynaecological and cancer procedures are continuing, and it is imperative all theatre staff are protected and risks of SARS-CoV-2 viral transmission reduced when operating on asymptomatic, suspected or confirmed COVID 19 patients. In particular, there are concerns relating to the transmission of COVID 19 during gynaecological laparoscopic surgery, arising from the potential generation of SARS-CoV-2 contaminated aerosols from CO2 leakage and the creation of smoke from the use of energy devices. The aim of this paper is to review all the up to date evidence, including experiences from China and Italy, to guide the safe management of such patients when undergoing gynaecological procedures."],"journal":"Facts Views Vis Obgyn","authors":["Mallick, R","Odejinmi, F","Clark, T J"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32259155","week":"202015|Apr 06 - Apr 12","keywords":["covid 19","coronavirus","laparoscopy","surgery"],"source":"PubMed","topics":["Prevention","Transmission"],"weight":1,"locations":["China","Italy"],"countries":["China","Italy"],"countries_codes":["CHN|China","ITA|Italy"],"_version_":1664640769759117313,"score":80.3584},{"pmid":32247898,"title":"Unknown unknowns - COVID-19 and potential global mortality.","text":["Unknown unknowns - COVID-19 and potential global mortality.","COVID-19 (SARS-CoV-2) is currently a global pandemic. This paper will attempt to estimate global infection rates and potential resultant mortality in the absence of effective treatment and/or vaccination. Calculations are based on World Health Organisation data from Wuhan in China: 14% of infected cases are severe, 5% require intensive care and 4% die. Estimated infection rates and mortality rates at the level of continents and some individual countries (when these are of sufficient size) are tabulated. This pandemic may cause close to half a billion deaths, i.e. 6% of the global population - and potentially more. At the risk of sounding sensational, but with a sober sense of realism, healthcare risks being plunged into the Middle-Ages if the public do not do their part. Infection cannot occur in the absence of contact. The only way to mitigate these numbers is to apply social distancing and take the standard precautions so frequently reiterated by Public Health: hand washing, avoid touching the face and so on. These measures are crucial as the human cost is going to be unthinkable even in the best-case scenarios that epidemiologists are modelling.","Early Hum Dev","Grech, Victor","32247898"],"abstract":["COVID-19 (SARS-CoV-2) is currently a global pandemic. This paper will attempt to estimate global infection rates and potential resultant mortality in the absence of effective treatment and/or vaccination. Calculations are based on World Health Organisation data from Wuhan in China: 14% of infected cases are severe, 5% require intensive care and 4% die. Estimated infection rates and mortality rates at the level of continents and some individual countries (when these are of sufficient size) are tabulated. This pandemic may cause close to half a billion deaths, i.e. 6% of the global population - and potentially more. At the risk of sounding sensational, but with a sober sense of realism, healthcare risks being plunged into the Middle-Ages if the public do not do their part. Infection cannot occur in the absence of contact. The only way to mitigate these numbers is to apply social distancing and take the standard precautions so frequently reiterated by Public Health: hand washing, avoid touching the face and so on. These measures are crucial as the human cost is going to be unthinkable even in the best-case scenarios that epidemiologists are modelling."],"journal":"Early Hum Dev","authors":["Grech, Victor"],"date":"2020-04-06T11:00:00Z","year":2020,"_id":"32247898","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.earlhumdev.2020.105026","source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664637850777288704,"score":57.99394}]}